Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(8):1151–1155. doi: 10.1038/bjc.1997.198

Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.

V Combaret 1, N Gross 1, C Lasset 1, K Balmas 1, R Bouvier 1, D Frappaz 1, C Beretta-Brognara 1, T Philip 1, M C Favrot 1, J L Coll 1
PMCID: PMC2222795  PMID: 9099963

Abstract

TRKA expression was evaluated on 122 untreated neuroblastomas by immunohistochemistry using an antibody with predetermined specificity. This procedure is simple and reliable for protein detection at cellular level in a routine clinical setting. Fourteen tumours were classified as benign ganglioneuroma with a restricted expression of TRKA on ganglion cells; these patients were excluded from the following analysis. A total of 108 tumours were classified as neuroblastoma or ganglioneuroblastoma; 74 expressed TRKA protein, which strongly correlated with low stage, absence of N-MYC amplification, age (<1 year), CD44 expression and favourable clinical outcome. In a univariate analysis including tumour stage, age, histology, N-MYC amplification, CD44 and TRKA expression, all parameters had significant prognostic value. The absence of TRKA expression on CD44-positive or N-MYC non-amplified tumours permits the characterization of a subgroup of patients with intermediate prognosis. However, in a multivariate analysis taking into consideration the prognostic factors mentioned above, CD44 and tumour stage were the only independent prognostic factors for the prediction of patients' event-free survival.

Full text

PDF
1151

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borrello M. G., Bongarzone I., Pierotti M. A., Luksch R., Gasparini M., Collini P., Pilotti S., Rizzetti M. G., Mondellini P., De Bernardi B. trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages. Int J Cancer. 1993 Jun 19;54(4):540–545. doi: 10.1002/ijc.2910540404. [DOI] [PubMed] [Google Scholar]
  2. Brodeur G. M., Azar C., Brother M., Hiemstra J., Kaufman B., Marshall H., Moley J., Nakagawara A., Saylors R., Scavarda N. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992 Sep 15;70(6 Suppl):1685–1694. doi: 10.1002/1097-0142(19920915)70:4+<1685::aid-cncr2820701607>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  3. Combaret V., Gross N., Lasset C., Frappaz D., Peruisseau G., Philip T., Beck D., Favrot M. C. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol. 1996 Jan;14(1):25–34. doi: 10.1200/JCO.1996.14.1.25. [DOI] [PubMed] [Google Scholar]
  4. Combaret V., Wang Q., Favrot M. C., Thiesse P., Philip I., Bouffet E., Bailly C., Bouvier R., Chauvin F., Zucker J. M. Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Cancer Clin Oncol. 1989 Nov;25(11):1607–1612. doi: 10.1016/0277-5379(89)90305-2. [DOI] [PubMed] [Google Scholar]
  5. Donovan M. J., Hempstead B. L., Horvath C., Chao M. V., Schofield D. Immunohistochemical localization of Trk receptor protein in pediatric small round blue cell tumors. Am J Pathol. 1993 Dec;143(6):1560–1567. [PMC free article] [PubMed] [Google Scholar]
  6. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971 Feb;27(2):374–378. doi: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  7. Favrot M. C., Combaret V., Goillot E., Lutz P., Frappaz D., Thiesse P., Thyss A., Dolbeau D., Bouffet E., Tabone E. Expression of integrin receptors on 45 clinical neuroblastoma specimens. Int J Cancer. 1991 Sep 30;49(3):347–355. doi: 10.1002/ijc.2910490306. [DOI] [PubMed] [Google Scholar]
  8. Favrot M. C., Combaret V., Lasset C. CD44--a new prognostic marker for neuroblastoma. N Engl J Med. 1993 Dec 23;329(26):1965–1965. doi: 10.1056/NEJM199312233292615. [DOI] [PubMed] [Google Scholar]
  9. Gross N., Beretta C., Peruisseau G., Jackson D., Simmons D., Beck D. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res. 1994 Aug 1;54(15):4238–4242. [PubMed] [Google Scholar]
  10. Kogner P., Barbany G., Dominici C., Castello M. A., Raschellá G., Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 1993 May 1;53(9):2044–2050. [PubMed] [Google Scholar]
  11. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  12. Nakagawara A., Arima-Nakagawara M., Scavarda N. J., Azar C. G., Cantor A. B., Brodeur G. M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993 Mar 25;328(12):847–854. doi: 10.1056/NEJM199303253281205. [DOI] [PubMed] [Google Scholar]
  13. Philip T., Bernard J. L., Zucker J. M., Pinkerton R., Lutz P., Bordigoni P., Plouvier E., Robert A., Carton R., Philippe N. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol. 1987 Feb;5(2):266–271. doi: 10.1200/JCO.1987.5.2.266. [DOI] [PubMed] [Google Scholar]
  14. Shimada H., Chatten J., Newton W. A., Jr, Sachs N., Hamoudi A. B., Chiba T., Marsden H. B., Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984 Aug;73(2):405–416. doi: 10.1093/jnci/73.2.405. [DOI] [PubMed] [Google Scholar]
  15. Suzuki T., Bogenmann E., Shimada H., Stram D., Seeger R. C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993 Mar 3;85(5):377–384. doi: 10.1093/jnci/85.5.377. [DOI] [PubMed] [Google Scholar]
  16. Tanaka T., Hiyama E., Sugimoto T., Sawada T., Tanabe M., Ida N. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Cancer. 1995 Sep 15;76(6):1086–1095. doi: 10.1002/1097-0142(19950915)76:6<1086::aid-cncr2820760625>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  17. Zucker J. M., Philip T., Bernard J. L., Michon J., Bouffet E., Gentet J. C., Lopez M., Coze C., Philip I., Bordigoni P. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients. Prog Clin Biol Res. 1991;366:543–551. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES